Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities-A Brief Report
The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5-10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treat...
Saved in:
Main Authors: | Maria Pokorska-Śpiewak (Author), Anna Dobrzeniecka (Author), Agnieszka Ogrodnik (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children
by: Maria Pokorska-Śpiewak, et al.
Published: (2024) -
Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017) -
Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
by: Yang CHT, et al.
Published: (2018) -
Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents
by: Jesús Quintero, et al.
Published: (2019) -
Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)
by: Sergio Vicente-Sánchez, et al.
Published: (2017)